Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis-Reference-Cited by-同舟云学术

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis

Published:2022-02-23 Issue:3 Volume:12 Page:727-740
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Blauvelt Andrew,Gooderham Melinda,Griffiths Christopher E. M.,Armstrong April W.,Zhu Baojin,Burge Russel,Gallo Gaia,Guo Jiaying,Garrelts Alyssa,Lebwohl Mark

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00690-5.pdf

Reference44 articles.

1. Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961-7 e5.

2. Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9(4):785–97.

3. Carrascosa JM, de la Cueva P, Herranz P, Labandeira J, Notario J. Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. J Dermatolog Treat. 2017;28(3):188–99.

4. Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.

5. Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol. 2013;44:74–81.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia;Journal of Dermatological Treatment;2024-07-30

2. Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study;JEADV Clinical Practice;2024-07-04

3. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis;Dermatology and Therapy;2024-06-22

4. The Best Psoriasis Medications Emerge;JAMA Dermatology;2024-01-01

5. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO);Dermatology and Therapy;2023-12-19